Skip to main content
. 2023 Aug 21;5(1):vdad102. doi: 10.1093/noajnl/vdad102

Figure 6.

Figure 6.

LMP400 and Niraparib offer improved bioavailability than current analogs. (A) Comparison of survival of HEK293 cells stably expressing common ATP-Binding Cassette (ABC) transporters upon treatment with LMP400, Topotecan, or SN-38. (B) Comparison of survival of HEK293 cells stably expressing common ABC transporters upon treatment with Niraparib or Olaparib.